Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients
Authors
Keywords
Advanced breast cancer, HER2−, HR+, Japanese, Letrozole, Palbociclib
Journal
International Journal of Clinical Oncology
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-12-04
DOI
10.1007/s10147-018-1353-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study
- (2018) Norikazu Masuda et al. CANCER SCIENCE
- Pretreatment monocyte counts and neutrophil counts predict the risk for febrile neutropenia in patients undergoing TPF chemotherapy for head and neck squamous cell carcinoma
- (2018) Marie Shimanuki et al. Oncotarget
- Characteristics and prognosis of Japanese female breast cancer patients: The BioBank Japan project
- (2017) Koshi Nakamura et al. JOURNAL OF EPIDEMIOLOGY
- 462PA POPULATION PHARMACOKINETIC (PK) ANALYSIS OF PALBOCICLIB (PD-0332991) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS
- (2017) W. Sun et al. ANNALS OF ONCOLOGY
- 116O Palbociclib (PAL) plus letrozole (L) as first-line (1L) therapy (tx) in postmenopausal Asian women with estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2-) metastatic breast cancer (mBC)
- (2016) S-A. Im et al. ANNALS OF ONCOLOGY
- Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients
- (2016) Kenji Tamura et al. CANCER SCIENCE
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- (2016) Massimo Cristofanilli et al. LANCET ONCOLOGY
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)
- (2016) Sunil Verma et al. ONCOLOGIST
- The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition
- (2016) Tomohiko Aihara et al. Breast Cancer
- Risk Factors for Predicting Severe Neutropenia Induced by Pemetrexed Plus Carboplatin Therapy in Patients with Advanced Non-small Cell Lung Cancer
- (2015) Hiroaki Ikesue et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies
- (2015) W. Hu et al. CLINICAL CANCER RESEARCH
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†
- (2014) F. Cardoso et al. ANNALS OF ONCOLOGY
- Average Values and Racial Differences of Neutrophil Lymphocyte Ratio among a Nationally Representative Sample of United States Subjects
- (2014) Basem Azab et al. PLoS One
- Clinically Relevant Genetic Variations in Drug Metabolizing Enzymes
- (2011) Navin Pinto et al. CURRENT DRUG METABOLISM
- Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer
- (2008) P. Jenkins et al. ANNALS OF ONCOLOGY
- Pharmacokinetics/Genotype Associations for Major Cytochrome P450 Enzymes in Native and First- and Third-generation Japanese Populations: Comparison With Korean, Chinese, and Caucasian Populations
- (2008) SP Myrand et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- White Blood Cell Count, Especially Neutrophil Count, as a Predictor of Hypertension in a Japanese Population
- (2008) Yoshimi TATSUKAWA et al. HYPERTENSION RESEARCH
- PhRMA White Paper on ADME Pharmacogenomics
- (2008) J. Andrew Williams et al. JOURNAL OF CLINICAL PHARMACOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More